You are here: Industry Insights > InhibRx

News List

Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with firstwordpharma
June 22, 2021
Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced initiation of a potential registration-enabling Phase 2 study of INBRX-109 in conventional chondrosarcoma.
Inhibrx Announces Phase 1 Dose Escalation Results of Novel Hexavalent OX40 Agonist americanpharmaceuticalreview
January 13, 2021
Inhibrx has announced results from Part 1 of the Phase 1 dose escalation trial of INBRX-106, a novel hexavalent OX40 agonist, in development for the treatment of solid tumors.
Inhibrx Announces Positive Interim Results from Chondrosarcoma Trial americanpharmaceuticalreview
November 24, 2020
Inhibrx has announced updated interim results from a Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with chondrosarcoma. Chondrosarcoma is an orphan disease and bone cancer with approximately 2,800 new patients ...
Inhibrx Announces Enrollment of First Patient in INBRX-101 Study americanpharmaceuticalreview
September 06, 2019
Inhibrx announced the enrollment of the first patient in a Phase 1 clinical trial of INBRX-101. INBRX-101 is an Fc-fusion protein-based therapeutic candidate comprised of a modified recombinant version...
Inhibrx Announces Agreement for INBRX-101 outside US, Canada with Chiesi Group americanpharmaceuticalreview
May 31, 2019
Inhibrx has entered into an agreement with Chiesi Farmaceutici. The agreement grants Chiesi Group an option to exclusively license, develop and commercialize INBRX-101 outside of ...
Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105 americanpharmaceuticalreview
February 20, 2019
Inhibrx announced dosing has begun in a Phase 1 dose-escalation clinical trial of INBRX-105. INBRX-105 is a novel, multispecific antibody therapeutic candidate that is both an antagonist of PD-L1 and .....
WuXi Biologics and Inhibrx Enter an Exclusive Partnership for GMP Manufacturing en-cphi.cn
September 11, 2018
The agreement showcases the expansive biologics pipeline of Inhibrx and the world leading technical expertise and capabilities of WuXi Biologics.
Five Prime cuts loose from InhibRx immuno-oncology deal fiercepharma
August 30, 2017
Five Prime hands back rights to GITR program including lead candidate FPA-154